Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 197

1.

Velocity of early BCR-ABL transcript elimination as an optimized predictor of outcome in chronic myeloid leukemia (CML) patients in chronic phase on treatment with imatinib.

Hanfstein B, Shlyakhto V, Lauseker M, Hehlmann R, Saussele S, Dietz C, Erben P, Fabarius A, Proetel U, Schnittger S, Krause SW, Schubert J, Einsele H, Hänel M, Dengler J, Falge C, Kanz L, Neubauer A, Kneba M, Stegelmann F, Pfreundschuh M, Waller CF, Spiekermann K, Baerlocher GM, Pfirrmann M, Hasford J, Hofmann WK, Hochhaus A, Müller MC; SAKK and the German CML Study Group.

Leukemia. 2014 Oct;28(10):1988-92. doi: 10.1038/leu.2014.153. Epub 2014 May 6.

PMID:
24798484
2.

BCR/ABL level at 6 months identifies good risk CML subgroup after failing early molecular response at 3 months following imatinib therapy for CML in chronic phase.

Kim DD, Hamad N, Lee HG, Kamel-Reid S, Lipton JH.

Am J Hematol. 2014 Jun;89(6):626-32. doi: 10.1002/ajh.23707. Epub 2014 Apr 10.

3.

Outcome prediction by the transcript level of BCR-ABL at 3 months in patients with chronic myeloid leukemia treated with imatinib--a single institution historical experience.

Yin XF, Ma QL, Mu QT, Shao L, Wang SS, Meng HT, Xu WL, Wang YG, Chen ZM, Chen FF, Jin J.

Leuk Res. 2014 Oct;38(10):1191-8. doi: 10.1016/j.leukres.2014.07.003. Epub 2014 Jul 29.

PMID:
25115808
4.

Early reduction of BCR-ABL mRNA transcript levels predicts cytogenetic response in chronic phase CML patients treated with imatinib after failure of interferon alpha.

Merx K, Müller MC, Kreil S, Lahaye T, Paschka P, Schoch C, Weisser A, Kuhn C, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.

Leukemia. 2002 Sep;16(9):1579-83.

5.

Which method better evaluates the molecular response in newly diagnosed chronic phase chronic myeloid leukemia patients with imatinib treatment, BCR-ABL(IS) or log reduction from the baseline level?

Qin YZ, Jiang Q, Jiang H, Li JL, Li LD, Zhu HH, Lai YY, Lu XJ, Liu YR, Jiang B, Huang XJ.

Leuk Res. 2013 Sep;37(9):1035-40. doi: 10.1016/j.leukres.2013.06.003. Epub 2013 Jun 26.

PMID:
23810191
6.

Determining the rise in BCR-ABL RNA that optimally predicts a kinase domain mutation in patients with chronic myeloid leukemia on imatinib.

Press RD, Willis SG, Laudadio J, Mauro MJ, Deininger MW.

Blood. 2009 Sep 24;114(13):2598-605. doi: 10.1182/blood-2008-08-173674. Epub 2009 Jul 22.

7.

BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.

Elias MH, Baba AA, Azlan H, Rosline H, Sim GA, Padmini M, Fadilah SA, Ankathil R.

Leuk Res. 2014 Apr;38(4):454-9. doi: 10.1016/j.leukres.2013.12.025. Epub 2014 Jan 6.

PMID:
24456693
8.

Serial monitoring of BCR-ABL transcripts in chronic myelogenous leukemia (CML) treated with imatinib mesylate.

Hardling M, Wei Y, Palmqvist L, Swolin B, Stockelberg D, Gustavsson B, Ekeland-Sjöberg K, Wadenvik H, Ricksten A.

Med Oncol. 2004;21(4):349-58.

PMID:
15579919
9.

Molecular monitoring of response to imatinib (Glivec) in chronic myeloid leukemia patients: experience at a tertiary care hospital in Saudi Arabia.

Khalil SH, Abu-Amero KK, Al Mohareb F, Chaudhri NA.

Genet Test Mol Biomarkers. 2010 Feb;14(1):67-74. doi: 10.1089/gtmb.2009.0126. Erratum in: Genet Test Mol Biomarkers. 2010 Apr;14(2):283.

PMID:
19943786
10.

Suitability of the PAXgene system to stabilize bone marrow RNA in imatinib-resistant patients with chronic myeloid leukemia.

Ernst T, Hoffmann J, Erben P, Hehlmann R, Hochhaus A, Müller MC.

Clin Chem Lab Med. 2008;46(3):318-22. doi: 10.1515/CCLM.2008.086.

PMID:
18303987
11.

ApoptomiRs expression modulated by BCR-ABL is linked to CML progression and imatinib resistance.

Ferreira AF, Moura LG, Tojal I, Ambrósio L, Pinto-Simões B, Hamerschlak N, Calin GA, Ivan C, Covas DT, Kashima S, Castro FA.

Blood Cells Mol Dis. 2014 Jun-Aug;53(1-2):47-55. doi: 10.1016/j.bcmd.2014.02.008. Epub 2014 Mar 11. Erratum in: Blood Cells Mol Dis. 2015 Dec;55(4):420.

PMID:
24629639
12.

Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

Hughes TP, Kaeda J, Branford S, Rudzki Z, Hochhaus A, Hensley ML, Gathmann I, Bolton AE, van Hoomissen IC, Goldman JM, Radich JP; International Randomised Study of Interferon versus STI571 (IRIS) Study Group.

N Engl J Med. 2003 Oct 9;349(15):1423-32.

13.

[Early monitoring of BCR-ABL transcript levels and cytogenetic in assessing the prognosis of chronic myeloid leukemia].

Huang Q, Zhang XY, Li Y, Wang XM.

Zhonghua Yi Xue Za Zhi. 2013 Oct 15;93(38):3049-53. Chinese.

PMID:
24417926
14.

Prognosis for patients with CML and >10% BCR-ABL1 after 3 months of imatinib depends on the rate of BCR-ABL1 decline.

Branford S, Yeung DT, Parker WT, Roberts ND, Purins L, Braley JA, Altamura HK, Yeoman AL, Georgievski J, Jamison BA, Phillis S, Donaldson Z, Leong M, Fletcher L, Seymour JF, Grigg AP, Ross DM, Hughes TP.

Blood. 2014 Jul 24;124(4):511-8. doi: 10.1182/blood-2014-03-566323. Epub 2014 May 23.

15.

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial.

Kantarjian HM, Hochhaus A, Saglio G, De Souza C, Flinn IW, Stenke L, Goh YT, Rosti G, Nakamae H, Gallagher NJ, Hoenekopp A, Blakesley RE, Larson RA, Hughes TP.

Lancet Oncol. 2011 Sep;12(9):841-51. doi: 10.1016/S1470-2045(11)70201-7. Epub 2011 Aug 17. Erratum in: Lancet Oncol. 2011 Oct;12(11):989.

PMID:
21856226
16.

A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response.

Press RD, Galderisi C, Yang R, Rempfer C, Willis SG, Mauro MJ, Druker BJ, Deininger MW.

Clin Cancer Res. 2007 Oct 15;13(20):6136-43.

17.

Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.

Klamová H, Poláková KM, Mužík J, Ráčil Z, Záčková D, Steinerová K, Karas M, Faber E, Demečková E, Michalovičová-Sninská Z, Voglová J, Demitrovičová L, Mikušková E, Tóthová E, Chudej J, Markuljak I, Cmunt E, Moravcová J, Dvořáková D, Michalová K, Jarošová M, Sťastná MM, Cetkovský P, Dušek L, Koza V, Trněný M, Indrák K.

Cancer Med. 2013 Apr;2(2):216-25. doi: 10.1002/cam4.59. Epub 2013 Feb 21.

18.

BCR-ABL mRNA levels at and after the time of a complete cytogenetic response (CCR) predict the duration of CCR in imatinib mesylate-treated patients with CML.

Press RD, Love Z, Tronnes AA, Yang R, Tran T, Mongoue-Tchokote S, Mori M, Mauro MJ, Deininger MW, Druker BJ.

Blood. 2006 Jun 1;107(11):4250-6. Epub 2006 Feb 7.

19.

Initial molecular response at 3 months may predict both response and event-free survival at 24 months in imatinib-resistant or -intolerant patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase treated with nilotinib.

Branford S, Kim DW, Soverini S, Haque A, Shou Y, Woodman RC, Kantarjian HM, Martinelli G, Radich JP, Saglio G, Hochhaus A, Hughes TP, Müller MC.

J Clin Oncol. 2012 Dec 10;30(35):4323-9. doi: 10.1200/JCO.2011.40.5217. Epub 2012 Oct 29.

20.

Molecular monitoring of response to imatinib (Glivec) in CML patients pretreated with interferon alpha. Low levels of residual disease are associated with continuous remission.

Paschka P, Müller MC, Merx K, Kreil S, Schoch C, Lahaye T, Weisser A, Petzold A, König H, Berger U, Gschaidmeier H, Hehlmann R, Hochhaus A.

Leukemia. 2003 Sep;17(9):1687-94.

PMID:
12970765

Supplemental Content

Support Center